BRCA1/2 tumor mutation and „BRCAness“ of triple negative breast cancer

04/2017

RNDr. Ing. Bc. Libor Staněk^1,2, doc. MUDr. Petra Tesařová, CSc¹

1. Onkologická klinika 1. LF UK a VFN, Praha

2. Ústav patologie, FN Královské Vinohrady, Praha

SUMMARY

Triple negative breast carcinoma accounts for approximately 15-20 % of all breast carcinoma and is characterized by loss of expression of a-estrogen, progesterone and HER2 receptors, predominantly low differentiation, mostly in the basal form of the subgroup. They are more common in younger women and are associated with the occurrence of hereditary or sporadic forms of breast cancer caused by a pathogenic mutation in the BRCA1 and BRCA2 gene or another genetic disorder leading to HR-deficient tumors.

KEY WORDS

triple negative breast cancer, BRCA1/2, mutations, BRCAness, platinum chemotherapy, PARP inhibitors